Abstract: The present invention relates to a process for the production of interferon beta, and to an interferon beta composition having a unique glycosylation pattern.

Abstract: This invention relates to a novel protein, termed INSP152, herein identified as a secreted protein, in particular, as a MAM domain containing protein and to the use of this protein and nucleic acid sequence from the encoding gene in the diagnosis, prevention and treatment.

Abstract: The invention relates to a process for the production of purified IL-18 binding protein (IL-18BP) from a fluid comprising affinity chromatography.

Abstract: The invention is based on the discovery that the human protein referred to herein as INSP153 protein is a lipocalin.

Abstract: The invention relates to the analytical determination of poloxamers in a liquid protein sample.

Abstract: This invention relates to a novel protein, termed INSP201, herein identified as a cell surface glycoprotein, and to the use of this protein and nucleic acid sequences from the encoding gene in the diagnosis, prevention and treatment of disease.

Abstract: The invention relates to a method for purifying recombinant human FSH or an FSH variant starting from crude FSH, comprising the following steps: 1. dye-affinity chromatography; 2. hydrophobic interaction chromatography; and 3. reverse phase chromatography.

Abstract: This present invention relates to a novel protein, termed INSP085, herein identified as an IL-8 like protein and to the use of this protein and nucleic acid sequence from the encoding genes in the diagnosis, prevention and treatment of disease.

Abstract: The present invention is related to macrogol glyceride pharmaceutical formulations containing benzothiazole derivatives. In particular, the invention is related to benzothiazole stearoyl macrogol pharmaceutical formulations, method of preparation and use thereof.

Abstract: This invention relates to novel uses of a protein sequence (INSP052EC), herein identified as an immunoglobulin domain-containing cell surface recognition, in the diagnosis, prevention and treatment of diseases, in particular those related to the excessive expression and/or secretion of cytokines.

Abstract: Use of IL-18 inhibitors in tumor metastasis is disclosed.

Abstract: A stabilized HSA-free liquid pharmaceutical composition is described, which comprises an interferon (IFN), wherein said formulation is a solution that comprises a buffer, an amino acid and an antioxidant. Preferably, the interferon is human recombinant IFN-beta.

Abstract: The invention relates to a process for the purification of IL-18 binding protein (IL-18BP) from a fluid using aqueous two-phase partitioning.

Abstract: In various embodiments, the present invention provides methods and compositions for treatment of autoimmune diseases, including rheumatoid arthritis, for example comprising administering to a patient in need of such treatment a TACI-Ig fusion molecule. In one embodiment, the TACI-Ig fusion molecule is administered in amount sufficient to slow, suppress or inhibit proliferation-inducing functions of BlyS and APRIL.

Abstract: The present invention relates, generally, to methods and compositions for detecting or treating mental disorders, such as schizophrenia or bipolar disorder. The present invention more particularly discloses the identification of human genes that can be used for the diagnosis, prevention and treatment of schizophrenia, bipolar disorder and related disorders, as well as for the screening of therapeutically active drugs to treat said disorders. The invention further discloses specific polymorphisms or alleles of the KCNQ3 gene that are related to schizophrenia or bipolar disorder, as well as diagnostic tools and kits based on these markers. The invention can be used in the diagnosis of or predisposition to, detection, prevention and/or treatment of schizophrenia, bipolar disorder and related disorders.

Abstract: The present invention is related to pharmaceutical Poloxamer hydrogel formulations containing an interferon. In particular, the invention relates to sustained release hydrogel formulations of interferon-beta, method of preparation and use thereof.

Abstract: A method of preparing a stabilized bulk solution of a monomeric protein is described, which consists in providing a bulk of monomeric protein in a buffer solution and adding an excipient to the bulk, wherein the excipient is selected from the group consisting of bacteriostatic agents, surfactants, isotonicity agents, amino acids, antioxidants and combinations thereof. Prefereably the monomeric protein is IFN-beta.

Abstract: The present invention relates to the use of a cytokine-1, preferably from the IL-1 family more preferably IL-1F7b, or an isoform, mutein, fused protein, functional derivative or fragment thereof, capable of binding to IL-18BP or a mutein, fused protein, functional derivative or fragment thereof and capable of inhibiting a receptor of a cytokine-2, cytokine-2 being a member of the IL-1 family, preferably IL-18, in the manufacture of a medicament for the treatment or prevention of a disease which is caused or aggravated by inducing said receptor of cytokine-2.

Abstract: This invention relates to methods for use in industrial production of proteins. Specifically, the present invention provides a method of recycling solid supports for cultivation of anchorage-dependent cells such as, e.g., microcarriers and Fibra-Cel® disks. Solid supports recycled by a method of the present invention allow obtaining a protein productivity level comparable to the productivity level obtained with non-recycled solid support. The method comprises the steps of rinsing with water, rinsing with a sodium hydroxide solution and second rinsing step with water.